Oncternal Therapeutics (FRA:GTU) Stock Based Compensation : €6.45 Mil (TTM As of Mar. 2024)

View and export this data going back to . Start your Free Trial

What is Oncternal Therapeutics Stock Based Compensation?

Oncternal Therapeutics's Stock Based Compensation for the three months ended in Mar. 2024 was €1.25 Mil. Its Stock Based Compensation for the trailing twelve months (TTM) ended in Mar. 2024 was €6.45 Mil.

Oncternal Therapeutics Stock Based Compensation Historical Data

The historical data trend for Oncternal Therapeutics's Stock Based Compensation can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Oncternal Therapeutics Stock Based Compensation Chart

Oncternal Therapeutics Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Stock Based Compensation

Get a 7-Day Free Trial

0.46

1.28

5.20

7.01

6.88

Oncternal Therapeutics Quarterly Data
	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24
Stock Based Compensation	Get a 7-Day Free Trial															1.77	1.55	1.61	2.04	1.25

Oncternal Therapeutics Stock Based Compensation Calculation

Stock Based Compensation is a way corporations use stock options to reward employees. It provides executives and employees the opportunity to share in the growth of the company and, if structured properly, can align their interests with the interests of the company's shareholders and investors, without burning the company's cash on hand.

Stock Based Compensation for the trailing twelve months (TTM) ended in Mar. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was €6.45 Mil.

Oncternal Therapeutics Stock Based Compensation Related Terms

Thank you for viewing the detailed overview of Oncternal Therapeutics's Stock Based Compensation provided by GuruFocus.com. Please click on the following links to see related term pages.

Oncternal Therapeutics (FRA:GTU) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Oncternal Therapeutics Inc (FRA:GTU) » Definitions » Stock Based Compensation

Comparable Companies

Traded in Other Exchanges

ONCT:USA

Address

12230 El Camino Real, Suite 230, San Diego, CA, USA, 92130

Website

https://www.oncternal.com

Oncternal Therapeutics Inc is a clinical-stage oncology company developing first-in-class, novel therapies that target a broad spectrum of cancers with a large unmet medical need. The Company's clinical pipeline includes zilovertamab, a humanized monoclonal antibody that binds to ROR1 (Receptor-tyrosine kinase-like Orphan Receptor 1), and ONCT-216, a small molecule inhibiting the biological activity of ETS-family transcription factor oncoproteins. The Company is also developing ONCT-808, a CAR-T (chimeric antigen receptor T-cells) product candidate that targets ROR1 and ONCT-534, a dual-action androgen receptor inhibitor product candidate for the treatment of castration-resistant prostate and other androgen receptor-driven cancers.

Oncternal Therapeutics (FRA:GTU) Headlines

No Headlines